Central Academy: Biology Project
Central Academy: Biology Project
BIOLOGY
PROJECT
PNEUMONIA
of smoking
diagnosis
P
Vaccines to prevent certain types of pneumonia are available. Other methods of
prevention include handwashing and not smoking. Treatment depends on the underlying
cause. Pneumonia believed to be due to bacteria is treated with antibiotics. If the
pneumonia is severe, the affected person is generally hospitalized. Oxygen therapy may be used
if oxygen levels are low.
Pneumonia affects approximately 450 million people globally (7% of the population) and results
in about 4 million deaths per year. Pneumonia was regarded by William Osler in the 19th century
as "the captain of the men of death". With the introduction of antibiotics and vaccines in the 20th
century, survival improved. Nevertheless, in developing countries, and among the very old, the
very young, and the chronically ill, pneumonia remains a leading cause of death. Pneumonia
often shortens suffering among those already close to death and has thus been called "the old
man's friend".
Cause
Pneumonia is due to infections caused primarily by bacteria or viruses and less commonly
by fungi and parasites. Although there are over 100 strains of infectious agents identified, only a
few are responsible for the majority of the cases. Mixed infections with both viruses and bacteria
may occur in roughly 45% of infections in children and 15% of
infections in adults. A causative agent may not be isolated in
approximately half of cases despite careful testing.
The term pneumonia is sometimes more broadly applied to
any condition resulting in inflammation of the lungs (caused
for example by autoimmune diseases, chemical burns or drug
reactions); however, this inflammation is more accurately
referred to as pneumonitis.
Factors that predispose to pneumonia include smoking, immunodeficiency, alcoholism, chronic
obstructive pulmonary disease, asthma, chronic kidney disease, liver disease, and old
age. Additional risk in children includes not being breastfeed, exposure to cigarettes or air
pollution, malnutrition, and poverty. The use of acid-suppressing medications – such as proton-
pump inhibitors or H2 blockers – is associated with an increased risk of
pneumonia. Approximately 10% of people who require mechanical ventilation develop ventilator
associated pneumonia, and people with gastric feeding tube have an increased risk of
developing of aspiration pneumonia. For people with specific variants of FER gene, the risk of
death is reduced in sepsis caused by pneumonia. However, for those with TLR6 variants, the risk
of getting Legionnaires' disease is increased.
Bacteria
Bacteria are the most-common cause of community-acquired pneumonia (CAP),
with Streptococcus pneumoniae isolated in nearly 50% of cases. Other commonly-isolated
bacteria include Haemophilus influenza in 20%, Chlamydophila pneumoniae in 13%,
and Mycoplasma pneumoniae in 3% of cases; Staphylococcus aureus; Moraxella
catarrhalis; Legionella pneumophila; and Gram-negative bacilli. A number of drug-
resistant versions of the above infections are becoming more common, including drug-
resistant Streptococcus pneumoniae (DRSP) and methicillin-resistant Staphylococcus
aureus (MRSA).
The spreading of organisms is facilitated when risk factors are present. Alcoholism is associated
with Streptococcus pneumoniae, anaerobic organisms, and Mycobacterium tuberculosis;
smoking facilitates the effects of Streptococcus pneumoniae, Haemophilus influenza, Moraxella
catarrhalis, and Legionella pneumophila. Exposure to birds is associated with Chlamydia psittaci;
farm animals with Coxiella Brunetti; aspiration of stomach contents with anaerobic organisms;
and cystic fibrosis with aeruginosa and Staphylococcus aureus. Streptococcus pneumoniae is
more common in the winter, and it should be suspected in persons aspirating a large amount of
anaerobic organisms.
Viruses
In adults, viruses account for approximately a third and in children for about 15% of pneumonia
cases. Commonly-implicated agents include rhinoviruses, coronaviruses, influenza
virus, respiratory syncytial virus(RSV), adenovirus, and parainfluenza. Herpes simplex
virus rarely causes pneumonia, except in groups such as: newborns, persons with cancer,
transplant recipients, and people with significant burns. People following organ transplantation or
those otherwise-immunocompromised present high rates of cytomegalovirus pneumonia. Those
with viral infections may be secondarily infected with the bacteria Streptococcus
pneumoniae, Staphylococcus aureus, or Haemophilus influenzae, particularly when other health
problems are present. Different viruses predominate at different periods of the year; during flu
season, for example, influenza may account for over half of all viral cases. Outbreaks of other
viruses also occasionally occur, including hantaviruses and coronavirus.
Fungi
Fungal pneumonia is uncommon, but occurs more commonly in individuals with weakened
immune systems due to AIDS, immunosuppressive drugs, or other medical problems. It is most
often caused by Histoplasma capsulatum, blastomyces, Cryptococcus
neoformans, Pneumocystis jiroveci (pneumocystis pneumonia, or PCP), and Coccidioides
imcites. Histoplasmosis is most common in the Mississippi River basin,
and coccidioidomycosis is most common in the Southwestern United States. The number of
cases has been increasing in the latter half of the 20th century due to increasing travel and rates
of immunosuppression in the population. For people infected with HIV/AIDS, PCP is a
common opportunistic infection.
Parasites
A variety of parasites can affect the lungs, including Toxoplasma gondii, Strongyloides
stercoralis, Ascaris lumbricoides, and Plasmodium malaria. These organisms typically enter the
body through direct contact with the skin, ingestion, or via an insect vector. Except
for Paragonimus westermani, most parasites do not affect specifically the lungs but involve the
lungs secondarily to other sites. Some parasites, in particular those belonging to
the Ascaris and Strongyloides genera, stimulate a strong eosinophilic reaction, which may result
in eosinophilic pneumonia. In other infections, such as malaria, lung involvement is due primarily
to cytokine-induced systemic inflammation. In the developed world these infections are most
common in people returning from travel or in immigrants. Around the world, these infections are
most common in the immunodeficient.
Non Infectious
Idiopathic interstitial pneumonia or non-infectious pneumonia is a class of diffuse lung diseases.
They include diffuse alveolar damage, organizing pneumonia, nonspecific interstitial
pneumonia, lymphocytic interstitial pneumonia, desquamative interstitial pneumonia, respiratory
bronchiolitis interstitial lung disease, and usual interstitial pneumonia. Lipoid pneumonia is
another rare cause due to lipids entering the lung. These lipids can either be inhaled or from
lipids within the body.
Mechanisms
Pneumonia frequently starts as an upper respiratory tract infection that moves into the lower
respiratory tract. It is a type of pneumonitis (lung inflammation). The normal flora of the upper
airway gives protection by competing with pathogens for nutrients. In the lower airways, reflexes
of the glottis, actions of complement protein sand immunoglobulins are important for protection.
Micro aspiration of contaminated secretions can infect the lower airways and cause pneumonia.
The virulence of the organism, amount of the organisms to start an infection and body immune
response against the infection all determines the progress of pneumonia.
Bacterial
Most bacteria enter the lungs via small aspirations of organisms residing in the throat or
nose. Half of normal people have these small aspirations during sleep. While the throat always
contains bacteria, potentially infectious ones reside there only at certain times and under certain
conditions. A minority of types of bacteria such as Mycobacterium tuberculosis and Legionella
pneumophila reach the lungs via contaminated airborne droplets. Bacteria can spread also via
the blood. Once in the lungs, bacteria may invade the spaces between cells and between alveoli,
where the macrophages and neutrophils (defensive white blood cells) attempt to inactivate the
bacteria The neutrophils also release cytokines, causing a general activation of the immune
system. This leads to the fever, chills, and fatigue common in bacterial pneumonia. The
neutrophils, bacteria, and fluid from surrounding blood vessels fill the alveoli, resulting in the
consolidation seen on chest X-ray.
Viral
Viruses may reach the lung by a number of different routes. Respiratory syncytial virus is
typically contracted when people touch contaminated objects and then they touch their eyes or
nose. Other viral infections occur when contaminated airborne droplets are inhaled through the
mouth or nose. Once in the upper airway, the viruses may make their way in the lungs, where
they invade the cells lining the airways, alveoli, or lung parenchyma. Some viruses such as
measles and herpes simplex may reach the lungs via the blood. The invasion of the lungs may
lead to varying degrees of cell death. When the immune system responds to the infection, even
more lung damage may occur. Primarily white blood cells, mainly mononuclear cells, generate
the inflammation. As well as damaging the lungs, many viruses simultaneously affect
other organs and thus disrupt other body functions. Viruses also make the body more susceptible
to bacterial infections; in this way, bacterial pneumonia can occur at the same time as viral
pneumonia.
Diagnosis
Pneumonia is typically diagnosed based on a combination of physical signs and a chest X-ray. In
adults with normal vital signs and a normal lung examination the diagnosis is unlikely. However,
the underlying cause can be difficult to confirm, as there is no definitive test able to distinguish
between bacterial and non-bacterial origin.
The World Health Organization has defined pneumonia in children clinically based on either
a cough or difficulty breathing and a rapid respiratory rate, chest in drawing, or a decreased level
of consciousness. A rapid respiratory rate is defined as greater than 60 breaths per minute in
children under 2 months old, greater than 50 breaths per minute in children 2 months to 1 year
old or greater than 40 breaths per minute in children 1 to 5 years old. In children, low oxygen
levels and lower chest in drawing are more sensitive than hearing chest crackles with
a stethoscope or increased respiratory rate. Grunting and nasal flaring may be other useful signs
in children less than five years old. Lack of wheezing is an indicator of Mycoplasma
pneumoniae in children with pneumonia, but as an indicator it is not accurate enough to decide
whether or not macrolide treatment should be used. The presence of chest pain in children with
pneumonia doubles the probability of Mycoplasma pneumoniae.
In general, in adults, investigations are not needed in mild cases. There is a very low risk of
pneumonia if all vital signs and auscultation are normal. In persons requiring
hospitalization, pulse oximetry, chest radiography and blood tests – including a complete blood
count, serum electrolytes, C-reactive protein level, and possibly liver function tests – are
recommended. Procalcitonin may help determine the cause and support who should receive
antibiotics. Antibiotics is encouraged if procalcitonin level reaches 0.25 μg/L, strongly
encouraged if it reaches 0.5 μg/L, and strongly discouraged if the level is below 0.10 μg/L. For
those with CRP less than 20 mg/L without convincing evidence of pneumonia, antibiotics are not
recommended.
The diagnosis of influenza-like illness can be made based on the signs and symptoms; however,
confirmation of an influenza infection requires testing. Thus, treatment is frequently based on the
presence of influenza in the community or a rapid influenza test.
Physical exam
Physical examination may sometimes reveal low blood pressure, high heart rate, or low oxygen
saturation. The respiratory rate may be faster than normal, and this may occur a day or two
before other signs. Examination of the chest may be normal, but it may show decreased chest
expansion on the affected side. Harsh breath sounds from the larger airways that are transmitted
through the inflamed lung are termed bronchial breathing and are heard on auscultation with
a stethoscope. Crackles (rales) may be heard over the affected area
during inspiration. Percussion may be dulled over the affected lung, and increased, rather than
decreased, vocal resonance distinguishes pneumonia from a pleural effusion.
Microbiology
In people managed in the community, determining the causative agent is not cost-effective and
typically does not alter management. For people who do not respond to treatment, sputum
culture should be considered, and culture for Mycobacterium tuberculosis should be carried out
in persons with a chronic productive cough. Microbiological evaluation is also indicated in severe
pneumonia, alcoholism, asplenia, immunosuppression, HIV infection, and alcohol
abuse. Although positive blood culture and pleural fluid culture definitively establish the diagnosis
of the type of micro-organism involved, a positive sputum culture has to be interpreted with care
for the possibility of colonisation of respiratory tract. Testing for other specific organisms may be
recommended during outbreaks, for public health reasons. In those hospitalized for severe
disease, both sputum and blood cultures are recommended, as well as testing the urine
for antigens to Legionella and Streptococcus. Viral infections can be confirmed via detection of
either the virus or its antigens with culture or polymerase chain reaction (PCR), among other
techniques. Mycoplasma, Legionella, Streptococcus, and Chlamydia can also be detected using
PCR techniques on Broncho alveolar lavage and nasopharyngeal swab. The causative agent is
determined in only 15% of cases with routine microbiological tests.
Classification
Pneumonitis refers to lung inflammation; pneumonia refers to pneumonitis, usually due to
infection but sometimes non-infectious, that has the additional feature of pulmonary
consolidation. Pneumonia is most commonly classified by where or how it was
acquired: community-acquired, aspiration, healthcare-associated, hospital-acquired,
and ventilator-associated pneumonia. It may also be classified by the area of lung affected: lobar
pneumonia, bronchial pneumonia and acute interstitial pneumonia; or by the causative
organism. Pneumonia in children may additionally be classified based on signs and symptoms as
non-severe, severe, or very severe.
The setting in which pneumonia develops is important to treatment, as it correlates to which
pathogens are likely suspects, which mechanisms are likely, which antibiotics are likely to work
or fail, and which complications can be expected based on the person's health status.
Healthcare
Health care–associated pneumonia (HCAP) is an infection associated with recent exposure to
the health care system, including hospital, outpatient clinic, nursing
home, dialysis centre, chemotherapy treatment, or home care. HCAP is sometimes called MCAP
(medical care–associated pneumonia).
Hospital
Hospital-acquired pneumonia is acquired in a hospital, specifically, pneumonia that occurs 48
hours or more after admission, which was not incubating at the time of admission. It is likely to
involve hospital-acquired infections, with higher risk of multidrug-resistant pathogens. Also,
because hospital people are often ill (which is why they are present in the hospital),
accompanying disorders are an issue.
Ventilator
Ventilator-associated pneumonia occurs in people breathing with the help of mechanical
ventilation. Ventilator-associated pneumonia is specifically defined as pneumonia that arises
more than 48 to 72 hours after endotracheal intubation.
Differential Diagnosis
Several diseases can present with similar signs and symptoms to pneumonia, such as: chronic
obstructive pulmonary disease (COPD), asthma, pulmonary edema, bronchiectasis, lung cancer,
and pulmonary emboli. Unlike pneumonia, asthma and COPD typically present with wheezing,
pulmonary edema presents with an abnormal electrocardiogram, cancer and bronchiectasis
present with a cough of longer duration, and pulmonary emboli presents with acute onset sharp
chest pain and shortness of breath. Mild pneumonia should be differentiated from upper
respiratory tract infection (URTI). Severe pneumonia should be differentiated from acute heart
failure. Pulmonary infiltrates that resolved after giving mechanical ventilation should point to heart
failure and atelectasis rather than pneumonia. For recurrent pneumonia, underlying lung
cancer, metastasis, tuberculosis, foreign body, immunosuppression, and hypersensitivity should
be sought after.
Prevention
Prevention includes vaccination, environmental measures and appropriate treatment of other
health problems. It is believed that, if appropriate preventive measures were instituted globally,
mortality among children could be reduced by 400,000; and, if proper treatment were universally
available, childhood deaths could be decreased by another 600,000.
Vaccination
Vaccination prevents against certain bacterial and viral pneumonias both in children and
adults. Influenza vaccines are modestly effective at preventing symptoms of
influenza, The Centre (CDC) recommends yearly influenza vaccination for every person
6 months and older. Immunizing health care workers decreases the risk of viral pneumonia
among their people.
Vaccinations against Haemophilus influenzae and Streptococcus pneumoniae have good
evidence to support their use. There is strong evidence for vaccinating children under the age of
2 against Streptococcus pneumoniae (pneumococcal conjugate vaccine). Vaccinating children
against Streptococcus pneumoniae has led to a decreased rate of these infections in adults,
because many adults acquire infections from children. A Streptococcus pneumoniae vaccine is
available for adults, and has been found to decrease the risk of invasive pneumococcal
disease by 74%, but there is insufficient evidence to suggest using the pneumococcal vaccine to
prevent pneumonia or death in the general adult population. The CDC recommends that young
children and adults over the age of 65 receive the pneumococcal vaccine, as well as older
children or younger adults who have an increased risk of getting pneumococcal disease. The
pneumococcal vaccine has been shown to reduce the risk of community acquired pneumonia in
people with chronic obstructive pulmonary disease (COPD), but does not reduce mortality or the
risk of hospitalization for people with this condition. People with COPD are suggested to have a
pneumococcal vaccination. Other vaccines for which there is support for a protective effect
against pneumonia include pertussis, varicella, and measles.
Medications
When influenza outbreaks occur, medications such as amantadine or rimantadine may help
prevent the condition; however are associated with side effects.
Zanamivir or oseltamivir decrease the chance that people who are exposed to the virus will
develop symptoms; however, it is recommended that potential side effects are taken into
account.
Other
Smoking cessation and reducing indoor air pollution, such as that from cooking indoors with
wood or dung, are both recommended. Smoking appears to be the single biggest risk factor
for pneumococcal pneumonia in otherwise-healthy adults. Hand hygiene and coughing into one's
sleeve may also be effective preventative measures. Wearing surgical masks by the sick may
also prevent illness.
Appropriately treating underlying illnesses (such as HIV/AIDS, diabetes mellitus,
and malnutrition) can decrease the risk of pneumonia. In children less than 6 months of age,
exclusive breast feeding reduces both the risk and severity of disease. In those with HIV/AIDS
and a CD4 count of less than 200 cells/uL the
antibiotic trimethoprim/sulfamethoxazole decreases the risk of Pneumocystis pneumonia and is
also useful for prevention in those that are immunocomprised but do not have HIV.
Testing pregnant women for Group B Streptococcus and Chlamydia trachomatis, and
administering antibiotic treatment, if needed, reduces rates of pneumonia in infants; preventive
measures for HIV transmission from mother to child may also be efficient. Suctioning the mouth
and throat of infants with meconium-stained amniotic fluid has not been found to reduce the rate
of aspiration pneumonia and may cause potential harm, thus this practice is not recommended in
the majority of situations. In the frail elderly good oral health care may lower the risk of aspiration
pneumonia. Zinc supplementation in children 2 months to five years old appears to reduce rates
of pneumonia.
For people with low levels of vitamin C in their diet or blood, taking vitamin C supplements may
be suggested to decrease the risk of pneumonia, although there is no strong evidence of
benefit. There is insufficient evidence to recommend that the general population take vitamin C to
prevent pneumonia.
For adults and children in the hospital who require a respirator, there is no strong evidence
indicating a difference between heat and moisture exchangers and heated humidifiers for
preventing pneumonia. There is no good evidence that one approach to mouth care is better
than others in preventing nursing home acquired pneumonia.
Management
Antibiotics by mouth, rest, simple analgesics, and fluids usually
suffice for complete resolution. However, those with other
medical conditions, the elderly, or those with significant trouble CURB-65
breathing may require more advanced care. If the symptoms
worsen, the pneumonia does not improve with home treatment, Symptom Points
or complications occur, hospitalization may be
required. Worldwide, approximately 7–13% of cases in children Confusion 1
result in hospitalization, whereas in the developed world between
22 and 42% of adults with community-acquired pneumonia are
Urea>7 mmol/l 1
admitted. The CURB-65 score is useful for determining the need
for admission in adults. If the score is 0 or 1, people can typically
be managed at home; if it is 2, a short hospital stay or close Respiratory
1
follow-up is needed; if it is 3–5, hospitalization is rate>30
recommended. In children those with respiratory distress or
oxygen saturations of less than 90% should be hospitalized. The SBP<90mmHg,
utility of chest physiotherapy in pneumonia has not yet been 1
DBP<60mmHg
determined. Non-invasive ventilation may be beneficial in those
admitted to the intensive care unit. Over-the-counter cough Age>=65 1
medicine has not been found to be effective, nor has the use
of zinc in children. There is insufficient evidence for mucolytic. There is no strong evidence to
recommend that children who have non-measles related pneumonia take Vitamin
A supplements. For those with sepsis, 30 ml/kg of crystalloid should be infused to
correct hypotension. Vitamin D, as of 2018 is of unclear benefit in children.
Bacterial
Antibiotics improve outcomes in those with bacterial pneumonia. First dose of antibiotics should
be given as soon as possible. Increased use of antibiotics, however, may lead to the
development of antimicrobial resistant strains of bacteria. Antibiotic choice depends initially on
the characteristics of the person affected, such as age, underlying health, and the location the
infection was acquired. Antibiotic use is also associated with side effects such as nausea,
diarrhoea, dizziness, taste distortion, or headaches. In the UK, treatment before culture
results with amoxicillin is recommended as the first line for community-acquired pneumonia,
with doxycycline or clarithromycin as alternatives. In North America, where the "atypical" forms of
community-acquired pneumonia are more common, macrolides , and doxycycline have displaced
amoxicillin as first-line outpatient treatment in adults. In children with mild or moderate
symptoms, amoxicillin taken by mouth remains the first line. The use of fluoroquinolones in
uncomplicated cases is discouraged due to concerns about side-effects and generating
resistance in light of there being no greater clinical benefit.
For those who require hospitalization and caught their pneumonia in the community the use of a
β-lactam such as cephazolin plus macrolide such as azithromycin or a fluoroquinolones is
recommended. Antibiotics by mouth and by injection appear to be similarly effective in children
with severe pneumonia.
The duration of treatment has traditionally been seven to ten days, but increasing evidence
suggests that shorter courses (3–5 days) may be effective for certain types of pneumonia and
may reduce the risk of antibiotic resistance. For pneumonia that is associated with a ventilator
caused by non-fermenting Gram-negative bacilli (NF-GNB), a shorter course of antibiotics
increases the risk of that pneumonia will return. Recommendations for hospital-acquired
pneumonia include third- and fourth-
generation cephalosporins, carbapenems, fluoroquinolones, aminoglycosides,
and vancomycin. These antibiotics are often given intravenously and used in combination. In
those treated in hospital, more than 90% improve with the initial antibiotics. For people with
ventilator-acquired pneumonia, the choice of antibiotic therapy will depend on the person's risk of
being infected with a strain of bacteria that is multi-drug resistant. The clinically stable
intravenous antibiotics should be switched to oral antibiotics. For those with Methicillin resistant
Staphylococcus aureus (MRSA) or Legionella infections, prolonged antibiotics may be beneficial.
The addition of corticosteroids to standard antibiotic treatment appears to improve outcomes,
reducing death and morbidity for adults with severe community acquired pneumonia, and
reducing death for adults and children with non-severe community acquired pneumonia. Side
effects associated with the use of corticosteroids include high blood sugar. They are therefore
recommended in adults with severe community acquired pneumonia. There is some evidence
that adding corticosteroids to the standard PCP pneumonia treatment may be beneficial for
people who are infected with HIV.
The use of granulocyte colony stimulating factor (G-CSF) along with antibiotics does not appear
to reduce mortality and routine use for treating pneumonia is not supported by evidence.
Viral
Neuraminidase inhibitors may be used to treat viral pneumonia caused by influenza viruses
(influenza A and influenza B). No specific antiviral medications are recommended for other types
of community acquired viral pneumonias including SARS coronavirus, adenovirus, hantavirus,
and parainfluenza virus. Influenza A may be treated with rimantadine or amantadine, while
influenza A or B may be treated with oseltamivir, zanamiviror peramivir. These are of most
benefit if they are started within 48 hours of the onset of symptoms. Many strains
of H5N1 influenza A, also known as avian influenza or "bird flu", have shown resistance to
rimantadine and amantadine. The use of antibiotics in viral pneumonia is recommended by some
experts, as it is impossible to rule out a complicating bacterial infection. The British Thoracic
Society recommends that antibiotics be withheld in those with mild disease. The use
of corticosteroids is controversial.
Aspiration
In general, aspiration pneumonitis is treated conservatively with antibiotics indicated only
for aspiration pneumonia. The choice of antibiotic will depend on several factors, including the
suspected causative organism and whether pneumonia was acquired in the community or
developed in a hospital setting. Common options include clindamycin, a combination of a beta-
lactam antibiotic and metronidazole, or an aminoglycoside. Corticosteroids are sometimes used
in aspiration pneumonia, but there is limited evidence to support their effectiveness.
Follow-up
The British Thoracic Society recommends that a follow-up chest radiograph is taken in people
with persistent symptoms, smokers, and people older than 50. American guidelines vary, from
generally recommending a follow-up chest radiograph to not mentioning any follow-up.
Prognosis
With treatment, most types of bacterial pneumonia will stabilize in 3–6 days. It often takes a few
weeks before most symptoms resolve. X-ray finding typically clear within four weeks and
mortality is low (less than 1%). In the elderly or people with other lung problems, recovery may
take more than 12 weeks. In persons requiring hospitalization, mortality may be as high as 10%,
and in those requiring intensive care it may reach 30–50%. Pneumonia is the most
common hospital-acquired infection that causes death. Before the advent of antibiotics, mortality
was typically 30% in those that were hospitalized. However, for those whose lung condition
deteriorates within 72 hours, the problem is usually due to sepsis. If pneumonia deteriorates after
72 hours, it could be due to nosocomial infection or exacerbation of other underlying co-
morbidities. About 10% of those discharged from hospital are readmitted due to underlying co-
morbidities such as heart, lung, or neurology disorders, or due to new onset of pneumonia.
Complications may occur in particular in the elderly and those with underlying health
problems. This may include, among others: empyema, lung abscess, bronchiolitis
obliterans, acute respiratory distress syndrome, sepsis, and worsening of underlying health
problems.